Literature DB >> 26219584

Renal impairment in different phenotypes of Wilson disease.

Honghao Wang1, Zhihua Zhou2, Jiyuan Hu3, Yongzhu Han4, Xun Wang2, Nan Cheng2, Yunfan Wu2, Renmin Yang2.   

Abstract

Wilson's disease (WD) is a rare autosomal recessive genetic disease resulting in the chronic deposition of copper in both liver and brain. This can lead to hepatic, neurologic, and psychiatric manifestations. Renal impairment can occur in any period of WD, but the mechanism is not yet known. In this study, we analyzed the clinical data of 691 newly diagnosed WD patients to investigate the blood urea nitrogen (BUN), creatinine (Cr), and uric acid (UA) levels in different subtypes of WD. This study included 691 newly diagnosed WD patients, 34 asymptomatic cases, and 127 healthy controls. The entire sample was assessed for serum levels of BUN, Cr, and UA. We found that the levels of BUN and Cr in WD patients who had neurological manifestations were higher (p < 0.001). In contrast, those patients presenting with a combined neurological and hepatic condition showed the lowest serum levels of UA (p = 0.026). There are differences in renal impairment between the endo-phenotypes of WD. Renal impairment can reflect differential copper deposition in organs other than the liver.

Entities:  

Keywords:  Blood urea nitrogen; Creatinine; Phenotypes; Uric acid; Wilson’s disease

Mesh:

Substances:

Year:  2015        PMID: 26219584     DOI: 10.1007/s10072-015-2322-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  20 in total

1.  Wilson's disease in children: 37-year experience and revised King's score for liver transplantation.

Authors:  Anil Dhawan; Rachel M Taylor; Paul Cheeseman; Pamela De Silva; Leah Katsiyiannakis; Giorgina Mieli-Vergani
Journal:  Liver Transpl       Date:  2005-04       Impact factor: 5.799

2.  Profound midbrain atrophy in patients with Wilson's disease and neurological symptoms?

Authors:  K Strecker; J P Schneider; H Barthel; W Hermann; F Wegner; A Wagner; J Schwarz; O Sabri; C Zimmer
Journal:  J Neurol       Date:  2006-04-10       Impact factor: 4.849

Review 3.  Ceruloplasmin in neurodegenerative diseases.

Authors:  Vadim Vassiliev; Zena Leah Harris; Paolo Zatta
Journal:  Brain Res Brain Res Rev       Date:  2005-11

Review 4.  Wilson's Disease.

Authors:  Peter Ferenci
Journal:  Clin Gastroenterol Hepatol       Date:  2005-08       Impact factor: 11.382

5.  Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London) Brain 1912: 34; 295-509.

Authors:  Alastair Compston
Journal:  Brain       Date:  2009-08       Impact factor: 13.501

6.  Phenotype-genotype correlations in patients with Wilson's disease.

Authors:  Peter Ferenci
Journal:  Ann N Y Acad Sci       Date:  2014-02-12       Impact factor: 5.691

7.  Oral zinc therapy normalizes serum uric acid level in Wilson's disease patients.

Authors:  S Umeki; R Ohga; Y Konishi; T Yasuda; K Morimoto; A Terao
Journal:  Am J Med Sci       Date:  1986-11       Impact factor: 2.378

8.  Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community-based survey.

Authors:  Andrea Winquist; Kyle Steenland; Anoop Shankar
Journal:  Mov Disord       Date:  2010-05-15       Impact factor: 10.338

9.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.

Authors:  B N Ames; R Cathcart; E Schwiers; P Hochstein
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

Review 10.  Diagnosis and phenotypic classification of Wilson disease.

Authors:  Peter Ferenci; Karel Caca; Georgios Loudianos; Georgina Mieli-Vergani; Stuart Tanner; Irmin Sternlieb; Michael Schilsky; Diane Cox; Frieder Berr
Journal:  Liver Int       Date:  2003-06       Impact factor: 5.828

View more
  5 in total

Review 1.  Clinical manifestations of Wilson disease in organs other than the liver and brain.

Authors:  Karolina Dzieżyc-Jaworska; Tomasz Litwin; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

Review 2.  Clinical presentations of Wilson disease.

Authors:  Samuel Shribman; Thomas T Warner; James S Dooley
Journal:  Ann Transl Med       Date:  2019-04

3.  Metabolomics profiles of patients with Wilson disease reveal a distinct metabolic signature.

Authors:  Gaurav V Sarode; Kyoungmi Kim; Dorothy A Kieffer; Noreene M Shibata; Tomas Litwin; Anna Czlonkowska; Valentina Medici
Journal:  Metabolomics       Date:  2019-03-12       Impact factor: 4.290

4.  Mutation spectrum of ATP7B gene in pediatric patients with Wilson disease in Vietnam.

Authors:  Nguyen Thi Mai Huong; Nguyen Pham Anh Hoa; Ngo Diem Ngoc; Nguyen Thi Phuong Mai; Pham Hai Yen; Hoàng Thị Vân Anh; Giang Hoa; Tran Minh Dien
Journal:  Mol Genet Metab Rep       Date:  2022-03-15

5.  Clinical observation and risk assessment after splenectomy in hepatolenticular degeneration patients associated with hypersplenism.

Authors:  Wanzong Zhang; Qingsheng Yu; Hui Peng; Zhou Zheng; Fuhai Zhou
Journal:  Front Surg       Date:  2022-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.